Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

POLATUZUMAB VEDOTIN-PIIQ for Diffuse large b-cell lymphoma: Side Effects & Safety Data

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

There are 2,228 adverse event reports in the FDA FAERS database where POLATUZUMAB VEDOTIN-PIIQ was used for Diffuse large b-cell lymphoma.

Most Reported Side Effects for POLATUZUMAB VEDOTIN-PIIQ

Side Effect Reports % Deaths Hosp.
Disease progression 753 23.7% 207 36
Off label use 484 15.2% 112 47
Death 367 11.5% 367 23
Covid-19 202 6.4% 66 50
Neutropenia 160 5.0% 44 25
Pyrexia 119 3.7% 34 38
Drug ineffective 118 3.7% 44 10
No adverse event 109 3.4% 1 0
Blood lactate dehydrogenase increased 108 3.4% 29 10
Febrile neutropenia 107 3.4% 26 41
Platelet count decreased 103 3.2% 29 36
Diarrhoea 95 3.0% 28 23
Lymphoma 91 2.9% 10 5
Neutrophil count decreased 90 2.8% 12 27
Neuropathy peripheral 87 2.7% 4 8

Other Indications for POLATUZUMAB VEDOTIN-PIIQ

Product used for unknown indication (395) Diffuse large b-cell lymphoma refractory (158) Diffuse large b-cell lymphoma recurrent (107) Non-hodgkin's lymphoma (57) B-cell lymphoma (51) Follicular lymphoma (32) Lymphoma (32) Diffuse large b-cell lymphoma stage iv (22) Richter's syndrome (15) Diffuse large b-cell lymphoma stage iii (14)

Other Drugs Used for Diffuse large b-cell lymphoma

RITUXIMAB (22,275) CYCLOPHOSPHAMIDE (16,598) DOXORUBICIN (15,213) VINCRISTINE (14,922) PREDNISONE (11,266) LENALIDOMIDE (7,858) ETOPOSIDE (4,698) PREDNISOLONE (4,086) CYTARABINE (3,857) DEXAMETHASONE (3,696)

Related Pages

POLATUZUMAB VEDOTIN-PIIQ Full Profile All Diffuse large b-cell lymphoma Drugs POLATUZUMAB VEDOTIN-PIIQ Demographics POLATUZUMAB VEDOTIN-PIIQ Timeline